Abstract

Context: Sarcoidosis is a systemic disorder characterized histologically by noncaseating granulomas. There is paucity of Indian data on cutaneous sarcoidosis. Aims: To describe the clinical, histopathological findings, and extracutaneous involvement in cutaneous sarcoidosis.

Materials and Methods: A retrospective study was done in patients of cutaneous sarcoidosis who had attended the dermatology clinic of a tertiary health care center in India from May 2009 to April 2015. The clinical details, histopathological findings, treatment, and response were reviewed.

Results: There were 38 patients with cutaneous sarcoidosis. Mean age was 48 ± 13 years; 58% were female. Median duration of disease was 11 months (IQR 4–48 months). More than one morphology was seen in 28.9%, commonest being plaques (65.7%), and papules (50%). Erythema nodosum was rare. More than one site was involved in 55.3%, most commonly trunk (52.6%). Six patients had isolated cutaneous sarcoidosis. Commonest extracutaneous organs involved were lung (73.7%) and lymph nodes (68.4%). Histopathologically, classical naked sarcoidal granulomas were found in only 55.3%. Angiotensin converting enzyme (ACE) levels were elevated in 74.3% (26/35) with significant association with extracutaneous disease. Treatment included topical and/or systemic corticosteroids, hydroxychloroquine, and tacrolimus. Statistics: Pearson’s Chi-square test was done to analyze associations between the skin lesions, ACE levels, and systemic involvement; P < 0.05 was considered significant. Conclusions: Cutaneous manifestations of sarcoidosis are varied, commonest being erythematous plaques. Even though most patients had systemic involvement, we found no significant association of the type and number of skin lesions with extracutaneous involvement or prognosis. Elevated ACE levels were significantly associated with systemic involvement.

Keywords: ACE levels, naked granulomas, sarcoidosis

Introduction

Sarcoidosis is a multisystem disorder of unknown etiology characterized by noncaseating granulomas on histopathology.[1] Skin is the most accessible and second most common organ involved in sarcoidosis.[2] The reported prevalence of cutaneous sarcoidosis is 20–35%.[1,2] Most of the studies on cutaneous sarcoidosis are from the West with relative paucity of Indian data.[1–6] Hence, we undertook this study to describe the clinical and histopathological spectrum of cutaneous sarcoidosis in our population and to look for any association between the various cutaneous lesions, systemic involvement, serum angiotensin converting enzyme (ACE) levels and prognosis.

Subjects and Methods

A retrospective study on cutaneous sarcoidosis between 1 May 2009 to 30 April 2015 (6 years) was conducted in the dermatology department of a tertiary care setting in South India. Patients in whom cutaneous sarcoidosis was clinically suspected and the histopathology showed the presence of epithelioid granulomas were included in the study after exclusion of infective causes like cutaneous tuberculosis, atypical mycobacterial infections, leishmaniasis, and deep fungal infections, by special stains and cultures for bacteria, mycobacteria, and fungi and non-infectious granulomatous conditions like granuloma annulare. Their clinical details, laboratory investigations, and...
histopathology were reviewed. Histopathologically, sarcoidosis was diagnosed based on non-caseating granulomatous inflammation and the features looked for were type of granulomas, whether naked or non-naked, discrete or confluent, and their location and depth and necrosis, if present.[7] Reticulin and mucin stain, if done, were also reviewed. The symptoms, clinical features, and systemic involvement were noted from the hospital records. Investigations like Mantoux test (performed using 2TU tuberculin), chest radiography, and ACE levels were reviewed. Chest X-ray staging was done based on the Siltzbach classification system.[8] Serum ACE levels more than 52 U/L were taken as elevated. The treatment given and the response to treatment were recorded and classified as complete resolution, persistent lesions, and relapse of lesions.

**Statistical methods**

Frequencies and percentages were reported for qualitative variables. Pearson’s Chi-square test was used to analyze associations between the type and extent of skin lesions with systemic involvement and elevated ACE levels. The P value less than 0.05 was considered as statistically significant. Analysis was done using SPSS version 16.0.

**Results**

There were 38 patients of cutaneous sarcoidosis during the six-year study period. The patient details are shown in Table 1. Mean age was 48 ± 13 years with a slight female preponderance (58%). Majorit (51%) of our patients were from the eastern states, followed by the southern (30%) and north eastern states of India (5.2%), 4 patients from Bangladesh, and 1 from Nepal. More than one anatomical region was involved in 55.2% patients. The sites involved were trunk (52.6%), face (44.7%), and upper limbs (44.7%). Isolated cutaneous sarcoidosis was found in 6 (15.8%) patients. Erythematous plaques (65.7%) [Figure 1a and b] and papules (50%) [Figure 2a and b] were the commonest specific skin lesion seen. Rare cutaneous presentations [Figure 3a and b] were seen in 5 patients (13.1%). Erythema nodosum was seen in only 2 patients (5.2%) and both had lung involvement. Multiple (>3) skin lesions were seen in 28 patients (73.7%). Lungs (73.7%) were the most common extracutaneous organ system involved followed by the lymph nodes (68.4%). The chest X-ray staging was stage 0 in 23.6% (n = 9) patients, stage 1 in 2.6% (n = 1), stage 2 in 63.2% (n = 24), and stage 3 in 10.6% (n = 4). Eye involvement was found in 5 cases of which 3 had uveitis, 1 had conjuctival granulomas, while both uveitis and conjunctival granulomas were noted in 1 patient. Mantoux test was negative in all cases. There was no significant association of systemic involvement and type of skin lesions (p = 0.40) or number of skin lesions (p = 0.13) or of lesions over the face with involvement of the respiratory tract (p = 0.456).

Elevated ACE levels were found in 74.3% (26/35) of those tested and were significantly associated with systemic involvement (p = 0.00) (especially lung involvement (p = 0.00) and lymph node involvement (p = 0.013)). All the patients with isolated cutaneous sarcoidosis were found to have normal ACE levels.

**Histopathology**

Table 2 illustrates comparison of histopathological findings with other studies. Naked granulomas [Figure 4a] were found in 55.3% (n = 21), while non-naked granulomas in 44.7% (n = 17). Cutaneous lesions in patients with non-naked granulomas included papules and plaques (n = 3), only plaques (n = 7), papules (n = 4), papules and plaques with depigmented lesions (n = 1), angiolupoid lesion (n = 1), and subcutaneous nodule (n = 1). Rare clinical presentations like depigmented lesions with plaques (n = 1), psoriasiform (n = 1), and scar (n = 1) showed naked granulomas. Perineural location of granulomas with special stains being negative for acid fast lepra bacilli was seen in 1 patient. Fibrinoid necrosis was seen in 15.7% (n = 6) and multinucleated giant cells [Figure 4b] in 94.7%. Foreign bodies were found in only 5 cases, under non-polarizing microscope. Reticulin staining [Figure 4c] was done in 23 patients, of which it was preserved or increased in 19 (82%). There was no clinico-pathological correlation with systemic features.
Treatment

Topical steroids with or without tacrolimus was given for the cutaneous lesions in all patients. Systemic steroids were given in 25 patients, 1 of whom had only cutaneous involvement while 24 had pulmonary involvement with or without other extracutaneous involvement. Ten patients received hydroxychloroquine in addition to systemic steroids, while 6 patients received hydroxychloroquine alone. Among the six patients with isolated cutaneous

| Table 1: Disease characteristics | Number (%) |
|---------------------------------|------------|
| **Characteristic**              |            |
| **Gender**                      |            |
| Male                            | 16 (42)    |
| Female                          | 22 (58)    |
| **Age (mean +/- SD in years)**  | 48 (+/-13) |
| **Age at onset (mean +/- SD in years)** | 46 (+/-13.5) |
| **Duration of disease (median; interquartile range) (in months)** | 11 (4-48) |
| **Type of skin lesion** (More than 1 morphology in n=11 (28.9%)) |            |
| 1. Plaques                      | 25 (65.7)  |
| 2. Papules                      | 19 (50)    |
| 3. Nodules                      | 5 (13.1)   |
| 4. Others (Depigmented macules 2, Psoriasiform 1, Scar 1, Angiolupoid 1) | 5 (13.1) |
| 5. Non-specific (Erythema nodosum) | 2 (5.2)    |
| **Number of skin lesions**      |            |
| 1. Up to three lesions          | 10 (26.4)  |
| 2. More than or equal to 4 lesions | 28 (73.7) |
| **Site of the lesion** (More than 1 region involved in n=21 (55.3%)) |            |
| 1. Torso                        | 20 (52.6)  |
| 2. Face                         | 17 (44.7)  |
| 3. Upper limb                   | 17 (44.7)  |
| 4. Lower limb                   | 14 (36.8)  |
| **Isolated cutaneous sarcoidosis** | 6 (15.8)   |
| **Systemic involvement** (more than 1 organ involved in n=29 (76.3%)) |            |
| 1. Lungs                        | 28 (73.7)  |
| 2. Lymph nodes (thoracic=19, extrathoracic=7) | 26 (84.4) |
| 3. Liver                        | 7 (18.4)   |
| 4. Spleen                       | 5 (13.2)   |
| 5. Eyes                         | 5 (13.2)   |
| 6. Others (Neurologic 2, Cardiac 2, bone marrow 1, salivary gland 1) | 6 (15.7) |
| **ACE levels (n=35)**           |            |
| ACE levels up to 52 U/L         | 9 (25.7)   |
| ACE >52 U/L                     | 26 (74.3)  |
| **Treatment**                   |            |
| Topicals (Steroids±Tacrolimus)  | 38 (100)   |
| Intralesional steroids          | 1 (2.6)    |
| Systemic steroids alone         | 15 (39.4)  |
| Systemic steroids + hydroxychloroquine | 10 (26.3) |
| Hydroxychloroquine alone        | 6 (15.7)   |
| **Response to treatment (cutaneous lesions)** |            |
| Resolved                        | 10 (26.3)  |
| Improving                       | 5 (13.2)   |
| Persistent                      | 3 (7.9)    |
| Relapsed                        | 4 (10.5)   |
| Lost to follow up               | 16 (42.1)  |

Values are given as number (%) unless otherwise specified
sarcoidosis, 3 were treated with hydroxychloroquine alone while 1 received systemic steroids for unresponsive lesions and the remaining 2 were treated with topicals alone.

**Follow-up**

The median follow-up period was 24 months (range: 3–120). Complete resolution of the cutaneous lesions was seen in 36.8% (n = 14) with relapse in 4 of these patients on tapering steroids, lesions were in resolving phase in 13.1% (n = 5), and persistent lesions were seen in 7.8% (n = 3). Of the patients who received hydroxychloroquine alone, 4 were lost to follow up, 1 had improving cutaneous lesions, while in another the skin lesions were persistent on follow up. Of the 6 patients with isolated cutaneous sarcoidosis, 3 patients were lost to follow up, 1 had persistent lesions, while 2 had complete resolution of their skin lesions. Lung function had improved in 33% (n = 13), 8% (n = 3) had worsening, and 13% (n = 3) had relapse after stopping the steroids. Sixteen patients did not review after primary evaluation. As the study was in a tertiary care center, and patients were from distant places, the patients preferred to follow up with their local physician once the diagnosis was established, and treatment plan was made.

**Discussion**

Sarcoidosis has a worldwide distribution, with varying presentations and outcomes across ethnic and geographic
groups. Most studies on cutaneous sarcoidosis are from the West with very little data from the other regions.\[^{9,13}\] Though previously considered less common, it is being increasingly recognized in Indian patients.\[^{13,5,6}\]

In our study, the mean age of presentation was 48 years, consistent with that of existing literature.\[^{3,13,14}\] Females constituted only a little more than half of our patients even though most studies have shown strong female preponderance.\[^{13,15,16}\] This could be due to the gender differences in health seeking behavior in our population.

The clinical features of our patients have been compared with other studies [Table 3]. There is a wide variation in the distribution as well as types of lesions across races. Majority of our patients (55.3%) had lesions over more than 1 body region, including the torso. The commonest cutaneous lesions in our study were plaques and papules as has been previously reported.\[^{13,16}\] Consistent with previous Indian data,\[^{3}\] erythema nodosum was uncommon in our study. The other rarer types seen were psoriasiform, hypopigmented macules, scar, and angiolupoid. Owing to the polymorphic nature of cutaneous sarcoidosis lesions, it is important to be aware of the varied clinical presentations including the rarer types.

The prevalence of systemic involvement in cutaneous sarcoidosis varies from 29–82%.\[^{13,16}\] Majority (85.2%) of our patients had systemic involvement, most commonly lungs and lymph nodes, similar to that reported in a few studies.\[^{16,17}\] As our study was conducted in a tertiary care center, it is likely that the patients with systemic symptoms were over-represented. There was no association of the type, distribution, or number of cutaneous lesions with extracutaneous involvement or disease prognosis as reported in a previous Indian study.\[^{3}\]

Cutaneous sarcoidosis also has a significant variation in its histopathological findings. In contrast with existing literature,\[^{9,18}\] classical naked granulomas described in sarcoidosis were found in only 55%. Necrosis in granuloma points toward an infective etiology, and is not classically described in sarcoidosis; however, it has been rarely reported.\[^{9,16,18,19}\] Perineural localization of granulomas (seen

---

**Table 3: Comparison with other studies**

| Characteristic                              | Present study | Mahajan et al., 2007\[^{3}\] | Collin et al., 2009\[^{14}\] | Ishak et al., 2014\[^{13}\] | Esteves et al., 2015\[^{18}\] | Garcia et al., 2019\[^{16}\] |
|--------------------------------------------|---------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|
| Number of patients                        | 38            | 23                            | 32                           | 76                           | 41                           | 40                           |
| Region/Ethnicity                          | Indian sub-continent | Indian         | White (57%), South Asian (28%), Afro-Caribbean (15%) | Lebanese                   | Spain                        | Caucasian (77.5%), African (12.5%), Caribbean (5%), Asian (5%) |
| Mean age (± SD in years)                  | 48 (± 13)     | 44 (range 31-78)              | 49 (range 27-84)             | 48 (range 19-74)             | 52 (+/-10)                   | 54 (range 26-79)              |
| Females (%)                               | 58            | 65                            | 74                           | 79                           | 83                           | 82.5                          |
| Types of lesion in cutaneous sarcoidosis (%) | Combination of papules, nodules, and plaques | Plaques                     | 44                           | 49                           | 22                           | 30                           |
| Papules                                   | 65            | 29                            | 49                           | 56                           | 56                           | 50                           |
| Nodules                                   | 50            | 29                            | 29                           | 18                           | 39                           | 30                           |
| More than 1 morphology                    | 13.2          | 18                            | 18                           | 34                           | 34                           | 35                           |
| Distribution of lesions (%)               | 28.9          | Widespread distribution (22/23) | 40                           | 31                           | 57.5                         | 57.5                         |
| More than 1 region                        | 55.3          | Torso (14)                    | 14                           | 14                           | 14                           | 35                           |
| Face                                      | 44.7          | Face (50)                     | 50                           | 46                           | 42.5                         | 42.5                         |
| Upper limbs                               | 44.7          | Upper limbs (25)              | 25                           | 25                           | 67.5                         | 67.5                         |
| Lower limbs                               | 36.8          | Lower limbs (21)              | 21                           | 21                           | 47.5                         | 47.5                         |
| Isolated cutaneous sarcoidosis (%)        | 15.7          | Isolated cutaneous sarcoidosis (%) | 29                           | 71                           | 41.5                         | 17.5                         |
| Systemic involvement (%)                  | 84.2          | Systemic involvement (%)      | 71                           | 29                           | 58.5                         | 82.5                         |
| Extra-cutaneous organs involved (%)       | Lungs         | Lungs (73.7)                  | 73                           | 53.6                         | 80                           |
|                                          | Lymph-nodes   | 68.4                          | 14                           | 24.3                         | 17.5                         |
|                                          | Liver         | 18.4                          | 18                           | 18                           | 18                           |
|                                          | Spleen        | 13.2                          | 13.2                         | 13.2                         | 13.2                         |
|                                          | Eyes          | 13.2                          | 13.2                         | 13.2                         | 13.2                         |
|                                          | Joints        | 15                            | 15                           | 15                           | 15                           |

---
in 1 of our cases) necessitating the exclusion of Hansen’s disease, has also been noted previously in sarcoidosis.\textsuperscript{[9,10,18]} Preserved or increased reticulin staining (in 82%) is useful in diagnosing sarcoidosis since disruption of reticulin network can be found in infectious processes.\textsuperscript{[20]}

Even though ACE levels are neither very sensitive nor specific for the diagnosis of sarcoidosis, our study corroborated previous studies, that elevated ACE levels correlate with systemic involvement.\textsuperscript{[14,15]}

This is the largest series of cutaneous sarcoidosis from the Indian subcontinent. The commonest clinical presentation was plaques and papules, involving more than 1 body region, including the torso. A multidisciplinary approach is important in the holistic management of this multisystem disorder.

**Financial support and sponsorship**

Nil.

**Conflicts of interest**

There are no conflicts of interest.

**References**

1. Haimovic A, Sanchez M, Judson MA, Prystowsky S. Sarcoidosis: A comprehensive review and update for the dermatologist: Part I. Cutaneous disease. J Am Acad Dermatol 2012;66:699.e1-18; quiz 717-8.
2. Maná MJ, Marcoval J. Skin manifestations of sarcoidosis. Presse Méd 2012;41:e355-74.
3. Mahajan VK, Sharma NL, Sharma RC, Sharma VC. Cutaneous sarcoidosis: Clinical profile of 23 Indian patients. Indian J Dermatol Venereol Leprol 2007;73:16-21.
4. Kumar R, Goel N, Gaur SN. Sarcoidosis in north Indian population: A retrospective study. Indian J Chest Dis Allied Sci 2012;54:99-104.
5. Mohanty R, Singh SN, Bhattachimshra AB. Cutaneous sarcoidosis without systemic manifestations. Indian J Dermatol 2009;54:80.
6. Reddy RR, Shashi Kumar BM, Harish MR. Cutaneous sarcoidosis-a great masquerader: A report of three interesting cases. Indian J Dermatol 2011;56:568-72.
7. Kumar V, Abbas AK, Aster JC, editors. Robbins Basic Pathology. 10th ed. Philadelphia: Elsevier; 2018. p. 512.
8. Siltzbach LE. Sarcoidosis: Clinical features and management. Med Clin North Am 1967;51:483-502.
9. Mangas C, Fernández-Figuera M-T, Fité E, Fernández-Chico N, Sábat M, Ferrándiz C. Clinical spectrum and histological analysis of 32 cases of specific cutaneous sarcoidosis. J Cutan Pathol 2006;33:772-7.
10. Jacyk WK. Cutaneous sarcoidosis in black South Africans. Int J Dermatol 1999;38:841-5.
11. Chong W-S, Tan H-H, Tan S-H. Cutaneous sarcoidosis in Asians: A report of 25 patients from Singapore. Clin Exp Dermatol 2005;30:120-4.
12. Tong C, Zhang X, Dong J, He Y. Comparison of cutaneous sarcoidosis with systemic sarcoidosis: A retrospective analysis. Int J Clin Exp Pathol 2014;7:372-7.
13. Ishak R, Kurban M, Kibbi A-G, Abbas O. Cutaneous sarcoidosis: Clinicopathologic study of 76 patients from Lebanon. Int J Dermatol 2015;54:33-41.
14. Collin B, Rajaratnam R, Lim R, Lewis H. A retrospective analysis of 34 patients with cutaneous sarcoidosis assessed in a dermatology department. Clin Exp Dermatol 2010;35:131-4.
15. Esteves TC, Aparicio G, Ferrer B, Garcia-Patos V. Prognostic value of skin lesions in sarcoidosis: Clinical and histopathological clues. Eur J J Dermatol 2015;25:556-62.
16. Garcia-Colmenero L, Sánchez-Schmidt JM, Barranco C, Pujol RM. The natural history of cutaneous sarcoidosis. Clinical spectrum and histological analysis of 40 cases. Int J Dermatol 2019;58:178-84.
17. Wu MC, Lee JY-Y. Cutaneous sarcoidosis in southern Taiwan: Clinicopathologic study of a series with high proportions of lesions confined to the face and angiolupoid variant. J Eur Acad Dermatol Venereol 2013;27:499-505.
18. Cardoso JC, Cravo M, Reis JP, Tellechea O. Cutaneous sarcoidosis: A histopathological study. J Eur Acad Dermatol Venereol 2009;23:678-82.
19. Ball NJ, Kho GT, Martinka M. The histologic spectrum of cutaneous sarcoidosis: A study of twenty-eight cases. J Cutan Pathol 2004;31:160-8.
20. Ko CJ, Glusac EJ. Non infectious granulomas. In: Elder DE, editor. Lever’s Histopathology of the Skin. 11th ed. Philadelphia: Wolters Kluwer; 2015. p. 438.